Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
A6NI03
UPID:
TR64B_HUMAN
Alternative names:
-
Alternative UPACC:
A6NI03
Background:
The Putative tripartite motif-containing protein 64B, encoded by the gene with the accession number A6NI03, represents a novel entity in the realm of molecular biology. Its classification within the tripartite motif-containing protein family suggests a potential role in ubiquitination processes, which are crucial for protein degradation, signaling pathways, and cellular homeostasis.
Therapeutic significance:
Understanding the role of Putative tripartite motif-containing protein 64B could open doors to potential therapeutic strategies. Its involvement in cellular processes pivotal for maintaining cellular integrity positions it as a candidate for targeted drug discovery efforts, aiming to modulate its activity for therapeutic benefits.